What Alfu-Kal Treats: Main Uses and Benefits

Alfu-Kal is primarily used to offer supportive, short-term relief across several distinct symptomatic areas. It is applied across domains where additional symptomatic support is needed, focusing on easing discomfort and helping patients manage episodes where symptoms become disruptive. For instance, the active ingredient, Alfuzosin, is indicated for relieving symptoms of an enlarged prostate (BPH), which are characterized by fluctuating, disruptive urinary patterns.

---

Easing Episodic Symptomatic Discomfort

This medicine is generally applied in situations involving symptoms related to physical discomfort that may intensify temporarily or appear suddenly. It is commonly used when short-term symptomatic assistance is needed during acute or recurrent episodes. This use contributes to improved comfort during periods of heightened symptoms and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Assists with Symptoms that Interfere with Daily Functioning

---

Managing Symptom Patterns and Heightened Tension

Alfu-Kal is relevant for managing symptom clusters that interfere with daily functioning and applied when symptoms create noticeable functional strain. It is often used when conditions are characterized by periods of heightened physiological activity or increased systemic burden, supporting the patient during phases of increased distress or discomfort. This application contributes to easing the overall symptom load and is relevant in settings where short-term symptom stabilization is important.

Regulatory References

1. NIH MedlinePlus Drug Information on Alfuzosin

Who can and cannot use Alfu-Kal?

This section describes the specific population groups who are eligible, restricted, or prohibited from using Alfu-Kal (Alfuzosin Hydrochloride) based only on official regulatory documentation.

Eligibility Scope

Classification	Eligibility Status (Regulatory Wording)
Populations for whom use is allowed	Adult male population for the treatment of associated conditions.
Populations for whom use is not recommended	Pediatric population (use is not indicated and efficacy was not established). Women (use is not indicated).
Populations for whom use is contraindicated	Patients with moderate or severe hepatic impairment. Patients with known hypersensitivity to alfuzosin. Patients concomitantly taking potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). Patients concomitantly taking other alpha-1 receptor blockers.
Age-related eligibility rules	Adults: Indicated for use. Pediatric (< 16 years): Not indicated; efficacy not established. Geriatric (> 65 years): Eligible; greater sensitivity of some older individuals cannot be ruled out.
Condition-specific eligibility rules	Moderate or severe hepatic impairment is a formal contraindication. Severe renal impairment (CrCl < 30 mL/min) requires caution (FDA) or is not recommended (EMA/HPRA). History of orthostatic hypotension is a contraindication.
Pregnancy and lactation eligibility status	Not applicable; the medicine is not indicated for use in women.

---

Eligibility-Context Constraints

The eligibility profile is defined by factors such as Organ Function Status and Concomitant Drug Use. The medicine is formally prohibited (contraindicated) for patients with moderate to severe liver impairment and for those simultaneously taking potent CYP3A4 inhibitors, as these conditions significantly increase drug concentration. Use is restricted by gender and age, as it is strictly for adult men and is not indicated for the pediatric population.

Interactions with other medicines and products

Official regulatory information indicates that Alfu-Kal (alfuzosin) has clinically important interactions with several classes of medications and products, primarily due to its effects on blood pressure and its metabolism by the liver enzyme CYP3A4.

---

Contraindicated Combinations

The following combinations are strictly prohibited due to the potential for serious adverse effects:

• Potent CYP3A4 Inhibitors: Co-administration with drugs like ketoconazole, itraconazole, and ritonavir is contraindicated. These medicines significantly increase alfuzosin blood levels, which can lead to dangerously low blood pressure (hypotension).
• Other Alpha-Adrenergic Antagonists: Use with other alpha-blockers is contraindicated due to the high risk of severe hypotension.

Combinations Requiring Caution

Caution and specific patient monitoring are required when Alfu-Kal is used concomitantly with:

• Phosphodiesterase-5 (PDE5) Inhibitors: Medications used for erectile dysfunction, such as sildenafil and tadalafil, should be used with caution because of the potential for additive blood pressure-lowering effects.
• Antihypertensive Medications and Nitrates: The use with other blood pressure-lowering agents and nitrates increases the risk of symptomatic hypotension and syncope.
• QT-Prolonging Medications: Caution is advised with medicines known to prolong the QT interval, as this combination may increase the risk of an electrical abnormality of the heart.

Food Interaction

The drug must be taken consistently with a meal, such as immediately after the same meal each day, because taking it on an empty stomach significantly alters its absorption.

The mechanism of Alfuzosin Hydrochloride is rooted in its modulation of the adrenergic system, producing localized effects on smooth muscle tone and decreasing dynamic resistance within the lower urinary tract.

Selective Alpha-1 Receptor Blockade

The mechanism begins at the molecular level through competitive antagonism of the alpha1-adrenergic receptors (alpha1-ARs), primarily the alpha1A subtype. The drug effectively prevents the endogenous neurotransmitter Norepinephrine from binding to and activating these receptors, which are densely located on smooth muscle cells in the prostate and bladder neck. This targeted alpha1-AR blockade initiates the cascade that alters the sympathetic signaling that governs muscle contraction.

Modulating Sympathetic Muscle Tone

The consequence of this molecular blockade is the interruption of sympathetically-driven muscle tone within the lower urinary tract. By inhibiting the signaling responsible for maintaining constant muscular tension, the drug causes smooth muscle relaxation in the prostate capsule and bladder neck. This physiological action modulates the dynamic component of resistance, resulting in a shift from a state of heightened contraction to one of sustained relaxation.

Modification of Urinary Tract Dynamics

The combined action of sustained alpha1-AR blockade and smooth muscle relaxation leads to a physiological decrease in the mechanical impedance of the urethra. This systemic change in mechanical impedance results in an increased luminal diameter and modified fluid dynamics. The prolonged-release formulation supports the mechanism by ensuring a consistent presence of the molecule for continuous receptor blockade over a 24-hour period.

How to Use Alfu-Kal: Official Administration Guidelines

Alfu-Kal (Alfuzosin Prolonged-Release Tablet) is administered via the oral route using a structured, once-daily protocol. The purpose of the prolonged-release design is to ensure a sustained therapeutic level over a 24-hour period, which dictates the key administration rules.

---

Standard Dosing and Administration Conditions

The standard regimen for adults involves taking one 10 mg prolonged-release tablet once daily. This is the maximum recommended dose for BPH symptom management with this formulation. To ensure the proper absorption required for the drug's intended action, the tablet must be taken immediately after the same meal each day.

---

Procedural Requirements and Tablet Integrity

To preserve the extended-release mechanism, which controls the drug's release over time, the tablet must be swallowed whole with an adequate amount of fluid. The tablet must not be crushed, chewed, split, or divided under any circumstances. If a dose is missed, the standard procedure is to skip the missed dose and take the next dose at the scheduled time; a double dose should not be taken to compensate.

---

Population and Use Restrictions

Administration is subject to specific functional limitations. The 10 mg prolonged-release tablet is contraindicated (must not be used) in patients with severe hepatic impairment. Furthermore, use is generally not recommended in patients with severe renal impairment (creatinine clearance less than 30 mL/min) due to limited safety data. The medication is not indicated for use in the pediatric population.

Evidence for Symptom Management in BPH/LUTS

The clinical research base for Alfu-Kal has primarily examined conditions characterized by fluctuating or episodic manifestations of LUTS associated with BPH. The evidence is built upon Randomized Controlled Trials (RCTs) and systematic reviews. Studies monitored patient-reported discomfort using validated questionnaires, such as the IPSS, and tracked functional outcomes like urinary flow rate ( Q max) and post-void residual volume ( PVRV). While findings describe patterns related to these functional measures, the follow-up durations for many core RCTs were limited. Consequently, long-term effects are not fully established, and there is limited information regarding influence on the physical size of the prostate.

---

Research on Acute Urinary Retention (AUR)

Alfu-Kal was also evaluated in research scenarios involving acute episodes, specifically spontaneous Acute Urinary Retention (AUR) requiring catheterization. Controlled trials observed patterns related to outcomes reflecting voiding status upon catheter removal, and studies monitored the need for surgery within a short time frame after the acute event. The key limitation here is that this evidence focuses heavily on the success of the acute intervention (Trial Without Catheter, or TWOC). Follow-up durations were limited, meaning the evidence contributes less to understanding the stability of symptoms beyond the initial months.

---

Evidence Gaps and Follow-up

Long-term follow-up data primarily comes from observational studies, as comparative evidence is lacking in extended duration RCTs. Research has explored the durability of symptom patterns over time intervals exceeding one year, though evidence quality varies across studies due to less controlled designs. Furthermore, research explored use in specific subgroups, including the older adult (geriatric) population, who were well-represented in pivotal clinical trials. However, data for certain groups remain insufficient, and certainty remains low regarding several aspects of long-term use.

Key Studies & References

1. Public Assessment Report Scientific discussion Alfuzosine HCl Aurobindo 10 mg, prolonged-release tablets (EMA/national agency document)

Common questions about Alfu-Kal (FAQ)

---

Q: Can Alfu-Kal be used by people who don't have the main condition it treats?

A: Alfu-Kal is officially indicated for the treatment of signs and symptoms of Benign Prostatic Hyperplasia (BPH) in adult men. This means its administration is limited to the medical condition for which it has been formally approved and studied by regulatory authorities.

Q: How does Alfu-Kal interact with alcohol?

A: Official information indicates that the use of alcohol can precipitate or worsen orthostatic hypotension (a drop in blood pressure when standing) associated with Alfu-Kal. Regulatory documents generally advise caution regarding alcohol consumption due to the potential for this effect.

Q: How quickly should someone expect Alfu-Kal to start working?

A: Alfu-Kal is a prolonged-release tablet, and its design ensures the active substance is released slowly over time. Clinical data suggests that steady-state levels in the body, which lead to a consistent therapeutic effect, are generally reached after the second dose is taken.

Q: Does Alfu-Kal have to be taken at the exact same time every day?

A: The official administration protocol is to take the tablet once daily immediately after the same meal each day. The purpose of this timing is to support consistent absorption required for the drug’s prolonged-release mechanism over the 24-hour period.

Q: Are there any specific foods or drinks that should be avoided when taking Alfu-Kal?

A: Regulatory documents explicitly require the tablet to be taken with food for proper absorption. Aside from alcohol, there are no specific foods or drinks listed in the official product information that are required to be avoided.

Q: What are the most commonly reported side effects of Alfu-Kal?

A: According to official clinical trial data, the most commonly reported effects (occurring in ge 1% to < 10% of patients) are dizziness, headache, asthenia (tiredness), nausea, and abdominal pain.

Q: Is it common to feel a little dizzy when first starting Alfu-Kal?

A: Dizziness is officially classified as a common side effect of Alfu-Kal. Postural hypotension (a drop in blood pressure when standing) can lead to dizziness or fainting and is explicitly noted in regulatory documents to occur mainly at the start of treatment.

Q: What kind of studies were done to get Alfu-Kal approved?

A: The regulatory approval was supported by comprehensive clinical development programs. This included randomized, double-blind, placebo-controlled, pivotal efficacy and safety studies using objective metrics like the International Prostate Symptom Score (IPSS).

Q: Is Alfu-Kal meant to be a long-term treatment?

A: While the initial controlled trials were short-term, open-label studies maintained clinical benefits for up to one year. Official use conditions support its administration for the ongoing management of symptoms.

Q: Is Alfu-Kal known to cause trouble sleeping?

A: Official adverse drug reaction reports list insomnia (trouble sleeping) as an uncommon side effect. This means it was reported in a very small percentage (ge 0.1% to < 1%) of participants in clinical studies.

Q: Can Alfu-Kal make you feel tired during the day?

A: Yes, tiredness, often listed as asthenia or fatigue in regulatory documents, is classified as a common side effect of Alfu-Kal, reported in ge 1% of patients during clinical trials.

Q: Why do doctors prescribe Alfu-Kal instead of other options?

A: Alfu-Kal is a selective alpha-blocker. Its mechanism of action specifically targets and induces the relaxation of smooth muscle in the prostate and bladder neck. This physiological action facilitates urination and provides relief from BPH symptoms.

Q: What is the physical appearance of the Alfu-Kal pill/tablet?

A: The prolonged-release tablet is described in official pharmaceutical documents as white to off-white, round, uncoated, and biconvex. It is often debossed with identifiers on one side for recognition.

Q: Does Alfu-Kal need to be stored in the refrigerator?

A: Official storage instructions state that Alfu-Kal should be stored below 25 C (77 F), at room temperature, and specifically must not be frozen. Refrigeration is not required to maintain its stability.

Q: Is Alfu-Kal available as a generic medicine?

A: Yes, regulatory records in many countries confirm that generic versions of alfuzosin prolonged-release tablets are approved and available. The availability and specific generic trade names may vary by region.

Q: Is it normal to feel no difference right away after starting Alfu-Kal?

A: Since Alfu-Kal is a prolonged-release tablet designed to provide continuous medication over 24 hours, the full therapeutic effect is not expected immediately after the very first dose. The drug's profile is based on reaching and maintaining consistent plasma levels after repeated administration.

Q: How long does the effect of one dose of Alfu-Kal typically last?

A: The formulation is designed as a prolonged-release tablet. This design ensures the active ingredient provides a sustained therapeutic level for continuous receptor blockade over a 24-hour period, supporting its once-daily administration.

Q: What should a person do if they accidentally take more Alfu-Kal than prescribed?

A: Regulatory documents describe the symptoms of overdosage, which are primarily related to significant hypotension (low blood pressure) and potential compensatory tachycardia (increased heart rate). The management of an overdosage event is described as requiring supportive and symptomatic care.

Q: Are there specific symptoms that mean I should stop taking Alfu-Kal immediately?

A: Regulatory documents state that if symptoms of new onset or worsening angina pectoris (chest pain) occur in patients with existing coronary artery disease, Alfu-Kal is to be discontinued.

Q: Do all people experience side effects from Alfu-Kal?

A: Clinical trial data reports adverse effects by incidence rate, which indicates the percentage of patients who experienced an effect. This means a majority of patients in clinical trials did not experience the most commonly listed side effects.

Q: Is there a patient information leaflet available for Alfu-Kal?

A: Yes, regulatory requirements in major markets mandate that a Patient Information Leaflet or Patient Medication Information is provided with all dispensed prescriptions of Alfu-Kal to ensure patients have access to official details about the drug.

Q: Is the main purpose of Alfu-Kal to manage symptoms or treat the underlying cause?

A: Alfu-Kal is classified as an alpha-blocker, and its purpose is to relieve the signs and symptoms associated with the condition it is indicated to treat. Its mechanism works to relax the smooth muscle in the urinary tract to improve urine flow.

Q: How much research evidence is there supporting Alfu-Kal's use?

A: Regulatory approval is supported by multiple pivotal randomized, placebo-controlled clinical trials, along with long-term open-label studies. This body of evidence was deemed sufficient by regulatory bodies to demonstrate a favorable benefit-risk profile for its use in the indicated population.

Q: Does Alfu-Kal contain any common allergens like gluten or lactose?

A: Official product information for the prolonged-release tablet often lists lactose as one of the excipients (inactive ingredients) in the formulation. This official information is included for patients with lactose sensitivity.

Q: What is known about Alfu-Kal's safety for people with kidney problems?

A: The drug is not recommended for people with severe renal impairment (creatinine clearance less than 30 mL/min). Official studies indicate that the safety profile in patients with mild or moderate renal impairment was similar to those with normal kidney function.

Q: What is known about Alfu-Kal's safety for people with liver problems?

A: Official documents state the drug is formally contraindicated (must not be used) in patients with moderate or severe hepatic impairment. Caution is also advised when considering its use in patients with mild hepatic impairment.

Q: Can Alfu-Kal affect my ability to drive or operate machinery?

A: Official warnings state that due to the potential for dizziness, lightheadedness, or fainting (syncope), patients should be cautious. Regulatory guidelines advise avoiding situations where injury could result, such as operating machinery or driving, until a consistent response to the treatment is established.

Storage and Disposal: Official Regulatory Requirements

Scope Element	Official Regulatory Requirement/Classification
Storage Temperature	Store below 25 C (77 F), at room temperature, and do not freeze.
Light/Moisture Protection	Must be protected from light and kept away from excess heat and moisture.
Packaging	Store in the original container and keep the container tightly closed.
Child Protection	Must be kept out of the sight and reach of children.
Shelf-Life	Do not use after the expiration date printed on the package.
Disposal Instructions	Do not discard via wastewater or household waste. Ask your pharmacist about authorized drug take-back or collection programs.

---

The stability of Alfu-Kal (Alfuzosin) is ensured by storing it within the prescribed temperature range and protecting it from environmental degradation caused by light and excessive moisture. The medicine must remain in its tightly closed original container. Disposal must follow procedures (such as drug take-back programs) that prevent the product from entering the household waste or water supply, as mandated for environmental protection.